Tun (10) showed improved OS, PFS, and ORR when adding CIT to chemotherapy for first-line NSCLC treatment, even among patients with EGFR alterations and ALK translocations, with incremental increase in adverse events (10). Here, ALK is linked to non-small cell lung carcinoma.